Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB652

Introduced
2/20/25  

Caption

Protecting Patients from Deceptive Drug Ads Act

Congress_id

119-S-652

Policy_area

Health

Introduced_date

2025-02-20

Companion Bills

No companion bills found.

Previously Filed As

US SB5040

Protecting Patients from Deceptive Drug Ads Online Act

US HB7766

Protecting Consumers from Deceptive AI Act

US SB4194

Protecting Communities from Plastics Act of 2024

US HB10018

POWER Act Protecting Our Wallets from Excessive Rates Act

US HB8384

Protect Elections from Deceptive AI Act

US HB6860

Restore Protections for Dialysis Patients Act

US HB757

Protecting Kids from Candy-Flavored Drugs Act

US HB7535

Prescription Drug Supply Chain Pricing Transparency Act

US HB5846

Protecting America from Seasonal and Pandemic Influenza Act of 2023

US HB7521

Protecting Americans from Foreign Adversary Controlled Applications Act

Similar Bills

US SB1702

Access to Prescription Digital Therapeutics Act of 2025

US SB3393

SUPPORT for Patients and Communities Reauthorization Act

US SB882

Patients Before Middlemen Act

US HB3162

Affordable and Safe Prescription Drug Importation Act of 2025

US HB950

Saving Seniors Money on Prescriptions ActThis bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.

US HB2214

DRUG Act Delinking Revenue from Unfair Gouging Act

US SB3950

DUALS Act of 2024 Delivering Unified Access to Lifesaving Services Act of 2024

US HB2554

Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).